Fatlossmaxxing — GLP-1 & Incretin Peptides for Research

Fatlossmaxxing — GLP-1, GIP, and glucagon receptor agonists: Semaglutide, Tirzepatide, Retatrutide, Cagrilintide.

Fatlossmaxxing is the term this catalog uses for the GLP-1 and multi-incretin receptor agonists at the center of modern fat-loss research. GLP-1 receptor agonists and their multi-agonist relatives (GIP, glucagon, amylin) are the most extensively studied weight-management compounds in modern endocrine research, with the registrational Phase 3 trials for Semaglutide, Tirzepatide, and Retatrutide reshaping the literature in the past five years. This category collects the GLP-class research peptides offered across the vendors tracked on the site, with side-by-side pricing per mg, dose-variant comparison, and notes on each vendor's Certificate of Analysis practice. Coverage spans the established agonists (Semaglutide), the dual-receptor compounds (Tirzepatide and Cagrilintide), and the investigational triple-receptor work (Retatrutide). Every entry is framed as research reference for parsing the published clinical and preclinical literature, not as a buying recommendation. Nothing on this page is medical advice; readers considering any of these compounds for any personal purpose should first consult a qualified clinician familiar with the regulatory status of the specific compound in their jurisdiction.